Viking Therapeutics, Inc. (NASDAQ:VKTX) Files An 8-K Regulation FD Disclosure

Viking Therapeutics, Inc. (NASDAQ:VKTX) Files An 8-K Regulation FD Disclosure
Item 7.01.Regulation FD.

On November 28, 2017, Viking Therapeutics, Inc. issued a press release announcing positive top-line results from its Phase 2 clinical trial of VK5211 in patients recovering from hip fracture. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number



Press Release dated November 28, 2017

Viking Therapeutics, Inc. Exhibit
EX-99.1 2 vktx-ex991_6.htm EX-99.1 vktx-ex991_6.htm   Exhibit 99.1   Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture   Study Achieves Primary Endpoint,…
To view the full exhibit click here

About Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

An ad to help with our costs